Pharmicell Co Ltd
Company Profile
Business description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Contact
12F Chungho B/D
3-2 Nonhyun-dong Gangnam-gu
Seoul135-010
KORT: +82 234960114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
161
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,321.10 | 10.80 | -0.12% |
CAC 40 | 8,229.49 | 29.37 | -0.36% |
DAX 40 | 24,322.75 | 7.28 | -0.03% |
Dow JONES (US) | 46,924.74 | 218.16 | 0.47% |
FTSE 100 | 9,489.53 | 62.54 | 0.66% |
HKSE | 25,807.71 | 219.84 | -0.84% |
NASDAQ | 22,953.67 | 36.88 | -0.16% |
Nikkei 225 | 49,307.79 | 8.27 | -0.02% |
NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
S&P 500 | 6,735.35 | 0.22 | 0.00% |
S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
SSE Composite Index | 3,913.76 | 2.57 | -0.07% |